Robert J Schwartz

This inventor holds 27 USPTO granted patents and 3 published patent applications, plus 6 CIPO patents and 3 EPO patents, primarily in Cardiac Regeneration. Top assignees: Baylor College of Medicine, University of Houston System, Animatus Biosciences, LLC. Active years: 1987-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert J Schwartz. Retrieved from https://idiyas.com/inventor/robert-j-schwartz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 3)

% Patents Active = 88.9

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 373(Granted Patents)

Company Filing History:

10 out of 619

Baylor College of Medicine

patents

8 out of 619

University of Houston System

patents

2 out of 3

Animatus Biosciences, LLC

patents

4. 2 out of 1,330

Texas A&M University System

patents

5. 2 out of 35

Texas Heart Institute

Vgx Pharmaceuticals, Inc.

patents

11. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2026

Loading Chart...

Areas of Expertise:

Cardiac Cell Proliferation

Viral Infections

Senescent Cells

Cardiomyocyte Regeneration

Rho Associated Kinase

Therapeutic miRNAs

Gene Therapy

Smooth Muscle Differentiation

Anemia Treatment

Transcriptional Regulatory Regions

Growth Hormone Releasing Hormone

Proportional Flow Control Valve

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692497 - CARDIAC CELL PROLIFERATION BY ADMINISTERING INHIBITORS OF SAV1, NF2, MOB1 AND/OR MUTANT SRF (2026-07-28),

2. 12569467 - Small molecules that treat or prevent viral infections (2026-03-10),

3. 12042525 - Serum response factor regenerates senescent cells (2024-07-23),

4. 11179479 - Enhanced cardiomyocyte regeneration (2021-11-23),

5. 10335449 - Rho associated kinase (ROCK) inhibitors and their use in treating disease (2019-07-02),

6. 10300147 - Therapeutic miRNAs for treating heart and skeletal muscle diseases (2019-05-28),

7. 9795690 - Therapeutic miRNAs for treating heart and skeletal muscle diseases (2017-10-24),

8. 9439924 - Therapeutic miRNAs for treating heart and skeletal muscle diseases (2016-09-13),

9. 9109232 - Ets2 and Mesp1 generate cardiac progenitors from fibroblasts (2015-08-18),

10. 8486701 - ETS2 and MESP1 generate cardiac progenitors from fibroblasts (2013-07-16),

11. 8178504 - Gene therapy expression of GHRH for increasing RBC count in subjects (2012-05-15),

12. 7960536 - Synthetic cell-or tissue-specific transcriptional regulatory regions (2011-06-14),

13. 7811820 - Smooth muscle cell differentiation with CRP, SRF and GATA factors (2010-10-12),

14. 7582478 - Cleaved serum response factor in cardiac diagnosis and therapy (2009-09-01),

15. 7338656 - Composition and method to alter lean body mass and bone properties in a subject (2008-03-04),

Title: The Innovative Work of Inventor Robert J Schwartz

Introduction:

Robert J Schwartz is a prolific inventor based in Houston, Texas, with a remarkable portfolio of 24 patents to his name. His groundbreaking research in the field of cardiomyocyte regeneration and the utilization of ROCK inhibitors has significantly advanced the medical field.

Latest Patents:

One of Schwartz's latest patents involves enhanced cardiomyocyte regeneration, where he developed compositions and methods to promote adult mammalian cardiomyocyte processes. By locally administering therapeutic agents containing modified messenger RNA, Schwartz aims to express mutated serum response factor and YAP polypeptides to stimulate cardiomyocyte proliferation and cardiac regeneration.

Another notable patent of Schwartz is the development of ROCK inhibitors for treating various disorders, including heart failure. His work on peptide inhibitors of Rho-associated-kinase, inhibiting ROCK1 activity and identifying novel inhibitory drugs, has promising implications for treating heart disease, pulmonary hypertension, glaucoma, and other critical conditions.

Career Highlights:

Robert J Schwartz's illustrious career includes significant contributions to Baylor College of Medicine and other prestigious institutions. His innovative research has garnered attention for its potential to revolutionize treatment approaches in cardiovascular and related diseases.

Collaborations:

Throughout his career, Schwartz has collaborated with leading experts in the field, including Ruxandra Draghia-Akli and Franco J DeMayo. These partnerships have further enriched his research endeavors and propelled his inventions to new heights.

Conclusion:

Inventor Robert J Schwartz's pioneering work in cardiomyocyte regeneration and ROCK inhibitors underscores his commitment to advancing medical science. With a track record of innovative patents and fruitful collaborations, Schwartz continues to make valuable contributions to the healthcare landscape.

Profile summary based on public USPTO records.